Equities

Jiangsu Yahong Meditech Co Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Jiangsu Yahong Meditech Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)11.98
  • Today's Change-0.07 / -0.58%
  • Shares traded5.29m
  • 1 Year change+68.50%
  • Beta1.5207
Data delayed at least 15 minutes, as of Feb 13 2026.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Jiangsu Yahong Meditech Co Ltd is a China-based company primarily engaged in innovative drugs in the fields of urogenital system tumors and women's health. The Company's product pipeline in women's health, breast cancer, and gynecologic oncology includes APL-1702, APL-2302, and APL-2501. Products in the field of urological oncology include contrast agents that assist in the diagnosis or surgery of bladder cancer, APL-1202/APL-1501, and APL-2401. Products in other disease areas include APL-1401 for ulcerative colitis, APL-2301 for treating infections caused by Acinetobacter baumannii, and APL-1202 for treating Entamoeba histolytica infections.

  • Revenue in CNY (TTM)279.02m
  • Net income in CNY-362.17m
  • Incorporated2010
  • Employees391.00
  • Location
    Jiangsu Yahong Meditech Co Ltd19F, Building B,Qiantan World Trade CentLane 221, Dongyu Road, Pudong New AreaSHANGHAI 200126ChinaCHN
  • Phone+86 2 168585280
  • Fax+86 2 168585281
  • Websitehttps://www.asieris.cn/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Qingdao Vland Biotech INC1.39bn83.57m3.96bn1.57k47.542.23--2.850.3290.3295.507.010.45853.893.65--3.764.846.116.9444.1945.528.209.540.877--0.264832.3510.169.30-22.39-4.23-2.71-6.89
Hinova Pharmaceuticals Inc23.61m-144.57m4.47bn173.00--4.06--189.15-1.46-1.460.238411.120.01712.375.59136,467.70-10.45-26.09-11.68-29.7495.50---612.36-78,863.606.90--0.0883-----38.6732.18--139.77--
Shanghai Aladdin Biochemical Tech Co Ltd599.98m83.95m5.28bn652.0063.824.95--8.790.24850.24851.783.210.27850.42184.55920,216.305.047.816.908.6062.2160.6118.0924.951.539.150.354148.3332.4420.5515.079.1741.61--
Hangzhou Alltest Biotech Co Ltd881.63m294.76m5.41bn969.0018.331.39--6.143.723.7211.1249.210.20982.386.39909,839.107.0219.187.5721.6655.0057.7933.4738.828.34--0.009335.1414.8329.1367.5030.9971.01--
Bide Pharmatech Co Ltd1.27bn153.31m5.43bn738.0033.982.71--4.271.761.7614.4922.030.51670.88045.251,720,520.006.247.027.528.2943.3042.1612.0713.132.78--0.105548.730.929834.697.17--80.65--
Shouyao Holdings Co Ltd2.14m-206.73m5.78bn178.00--8.83--2,697.32-1.39-1.390.01444.400.00250.03660.262512,033.88-23.67-32.53-27.20-36.2595.7499.43-9,651.03-3,370.016.42--0.0044---24.61-19.34-14.21--49.71--
Jiangsu Yahong Meditech Co Ltd279.02m-362.17m6.84bn391.00--3.86--24.52-0.642-0.6420.49333.100.12511.164.19713,603.90-16.84-14.30-19.15-15.0172.2273.78-134.65-703.804.96--0.1545--1,365.55--4.09--50.48--
GemPharmatech Co Ltd752.70m121.51m6.98bn1.58k56.613.17--9.270.30070.30071.865.370.28074.511.88476,993.404.537.695.428.9661.8468.1716.1425.583.17--0.129521.9410.3928.94-30.8925.8820.02--
Beijing Sun-Novo Pharma Research Co Ltd1.02bn133.01m7.46bn1.36k54.876.42--7.341.211.219.2310.380.474535.481.28653,956.406.0411.3910.4918.8248.6053.3112.7219.661.789.970.335511.2915.7035.80-3.9830.213.50--
Shanghai Medicilon Inc1.08bn-231.86m8.93bn2.27k--4.33--8.27-1.75-1.758.0415.360.37598.561.68459,338.00-8.083.66-9.994.6316.2731.15-21.496.672.19--0.150840.97-24.0118.22-896.21--2.54--
Data as of Feb 13 2026. Currency figures normalised to Jiangsu Yahong Meditech Co Ltd's reporting currency: Chinese Yuan Renminbi CNY

Institutional shareholders

5.28%Per cent of shares held by top holders
HolderShares% Held
Penghua Fund Management Co., Ltd.as of 30 Jun 20259.74m3.45%
China Universal Asset Management Co., Ltd.as of 30 Jun 20252.07m0.73%
Guotai Asset Management Co., Ltd.as of 30 Jun 2025881.87k0.31%
Zhong Ou Asset Management Co., Ltdas of 30 Jun 2025559.38k0.20%
AXA-SPDB Investment Managers Co., Ltd.as of 30 Jun 2025321.99k0.11%
Fullgoal Fund Management Co., Ltd.as of 30 Jun 2025317.07k0.11%
China Life AMP Asset Management Co., Ltd.as of 30 Jun 2025300.00k0.11%
New China Fund Management Co., Ltd.as of 30 Jun 2025277.81k0.10%
Shanghai Guotai Junan Securities Assets Management Co., Ltd.as of 30 Jun 2025249.43k0.09%
Huatai-PineBridge Fund Management Co., Ltd.as of 30 Jun 2025220.52k0.08%
More ▼
Data from 30 Jun 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.